文献速递神经肿瘤

复发与非复发脑膜瘤中CDKN2A基因改变的分析

Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma.
PubMed 文献 · J Neurooncol · 2019-11-15

该研究比较17例复发与13例非复发脑膜瘤的CDKN2A单核苷酸变异、缺失、启动子甲基化及p16表达,发现一种未在脑膜瘤中报道过的p.(Ala148Thr)突变仅见于复发肿瘤,且三种CDKN2A改变(该突变、纯合或杂合全基因缺失、启动子甲基化>8%)与复发及Ki67指数>7%相关,作者认为需扩大样本验证其作为复发标志物的价值。

要点

  • 在5例脑膜瘤中检出CDKN2A p.(Ala148Thr)突变,与复发显著相关(p=0.03)。
  • 三种CDKN2A改变(p.(Ala148Thr)突变、全基因纯合或杂合缺失、启动子甲基化>8%)见于17例复发脑膜瘤中的13例,与复发强相关(p<0.0001)。
  • 上述CDKN2A改变与Ki67标记指数>7%相关(p=0.004)。

核心结论

  • 本研究报道了一种未在脑膜瘤中描述过的CDKN2A p.(Ala148Thr)突变,该突变仅存在于复发肿瘤中。
  • 在本系列中,CDKN2A基因改变仅见于复发脑膜瘤。
  • 作者认为,结果需在更大样本中评估,以确保这些CDKN2A改变可作为脑膜瘤复发的生物标志物。

研究设计与样本

  • 对17例复发和13例非复发脑膜瘤进行对比分析。
  • 检测CDKN2A单核苷酸变异(SNVs)、缺失、启动子甲基化状态及p16表达。
  • 结果与复发或非复发状态及临床病理数据作相关性分析。

主要发现

  • 在5例脑膜瘤中鉴定出CDKN2A SNV(NM_000077,外显子2,c.G442A,p.Ala148Thr),与复发显著相关(p=0.03)。
  • 该突变经Sanger测序确认,并见于COSMIC数据库中多种癌症,但在脑膜瘤中尚未报道。
  • 三种CDKN2A改变之一(p.(Ala148Thr)突变、全基因纯合或杂合缺失、启动子甲基化>8%)见于17例复发脑膜瘤中的13例,与复发强相关(p<0.0001)。
  • 上述三种CDKN2A改变与Ki67标记指数>7%相关(p=0.004)。

关键数值与推荐

  • CDKN2A p.(Ala148Thr)突变在5例脑膜瘤中检出,与复发显著相关(p=0.03)。
  • 三种CDKN2A改变(p.(Ala148Thr)突变、全基因纯合或杂合缺失、启动子甲基化>8%)见于17例复发脑膜瘤中的13例,与复发强相关(p<0.0001)。
  • 三种CDKN2A改变与Ki67标记指数>7%相关(p=0.004)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出,结果需在更大样本中评估,以确保这些CDKN2A改变可作为脑膜瘤复发的生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Assessment of the risk of recurrence is essential to determine the therapeutic strategy of meningioma treatment. Many relapsing or aggressive meningiomas show elevated mitotic and/or Ki67 indices, reflecting cell cycle deregulation. As CDKN2A is a key tumor suppressor gene involved in cell cycle control, we investigated whether CDKN2A alterations may be involved in tumor recurrence. METHODS: We carried out a comparative analysis of 17 recurrent and 13 non-recurrent meningiomas. CDKN2A single nucleotide variations (SNVs), deletions, methylation status of the promotor, and p16 expression were investigated. Results were correlated with the recurrent or non-recurrent status and clinicopathological data. RESULTS: We identified a CDKN2A SNV (NM_000077, exon2, c.G442A, p.Ala148Thr) in five meningiomas that was significantly associated with recurrence (p = 0.03). This mutation, confirmed by Sanger sequencing and referenced in the COSMIC database in various cancers, has not been reported in meningioma. The presence of one of the three following CDKN2A alterations-p.(Ala148Thr) mutation, whole homozygous or heterozygous gene loss, or promotor methylation > 8%-was observed in 13 of the 17 relapsing meningiomas and was strongly associated with recurrence (p < 0.0001) and a Ki67 labeling index > 7% (p = 0.004). CONCLUSION: We report an undescribed p.(Ala148Thr) CDKN2A mutation in meningioma that was only present in relapsing tumors. In our series, CDKN2A gene alterations were only found in recurrent meningiomas. However, our results need to be evaluated on a larger series to ensure that these CDKN2A alterations can be used as biomarkers of recurrence in meningioma.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Guyot A, Duchesne M, Robert S, et al. Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma. J Neurooncol. 2019. PMID: 31729637. doi:10.1007/s11060-019-03333-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。